AxioMed gathers all Freedom Lumbar Disc 2-year follow-up data; sights set on FDA premarket approval — 6 observations

AxioMed gathered all of the two-year follow-up data on the Freedom Lumbar Disc for its USA investigational device exemption clinical study.

Advertisement

Here are six observations:

 

1. AxioMed now hopes to receive FDA premarket approval for its viscoelastic lumbar disc.

 

2. The viscoelastic disc, called the Freedom Disc, already received the CE Mark in 2009.

 

3. Surgeons have implanted the disc in more than 500 patients in Europe with more than seven-year follow-up data.

 

4. International Journal of Spine Surgery published the results of the European post-market study, revealing significant improvement in pain and disability in patients with the disc.

 

5. The study also found the disc helped restore the center of rotation.

 

6. Malden, Mass.-based KICVentures acquired AxioMed in 2014, but AxioMed still owns an exclusive viscoelastic material license on its proprietary Freedom Disc technology.

 

More articles on devices:
Medovex, AlfaMed, & more: 4 recent device company partnerships
Reprocessed medical devices market gaining traction — 4 observations
4 things to know about Intelligent Implant Systems

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new product launches and leadership appointments, here are seven key headlines from Stryker in the first quarter of 2026.…

  • Xtant Medical’s 2025 revenue reached $133.9 million, a 14% increase year over year, according to financial results posted March 31.…

Advertisement

Comments are closed.